We are a clinical-stage oncology company pioneering a novel class of therapeutics based on our proprietary DNA interference (DNAi®) technology platform. Our vision is to be the leader in developing and commercializing a portfolio of DNAi-based therapies to deliver extraordinary therapeutic outcomes that dramatically change patients’ lives.
Our lead DNAi product candidate, PNT2258, targets BCL2, a widely overexpressed oncogene that is an important gatekeeper of the programmed cell death process known as apoptosis and has been linked to many forms of cancer. We believe the preliminary evidence of efficacy, safety and tolerability observed to date suggest that PNT2258 has the potential to change treatment paradigms across a wide range of oncology indications. We are enrolling patients in Wolverine, a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma, and in Brighton, a Phase 2 trial evaluating PNT2258 for the treatment of Richter’s transformation.